Cancer Genomics and Diagnostics

SEP 8, 2026 · JOURNAL ARTICLE

Sex, Timing, and Outcomes of Curative-Intent Immunotherapy

JAMA Network Open

Large, rigorous meta-analysis of 38 randomized phase 3 trials with 31,721 patients showing statistically significant OS and disease-free survival benefits from ICIs in curative solid tumors, with no sex difference detected, though female underrepresentation limits generalizability.

SEP 8, 2026 · REVIEW

Economic evaluations of next-generation sequencing for targeted therapy in non-small cell lung cancer: a systematic review

Frontiers in Public Health

Systematic review of economic evidence synthesizing 18 model-based evaluations to inform policy on NGS adoption in NSCLC, with contextual conclusions about cost-effectiveness variability rather than a single definitive clinical or economic finding.

SEP 8, 2026 · JOURNAL ARTICLE

Beyond CA-125: circulating cell-free DNA as the next-generation biomarker in ovarian malignancy

BMC Cancer

A prospective case–control study of modest size (150 participants) with clear separation between groups and strong ROC performance for a candidate biomarker, but surrogate endpoints (AUC, survival association) rather than a clinical trial of intervention, requiring confirmation in independent cohorts.

SEP 7, 2026 · JOURNAL ARTICLE

Precision Oncology in Non-Small Cell Lung Cancer: Integrating Molecular Diagnostics, Targeted Therapies, and Resistance Mechanisms

Genes

A structured narrative review synthesizing evidence from 99 foundational studies and clinical documents to provide organized guidance on molecular biomarkers, diagnostic methods, and resistance mechanisms in NSCLC precision oncology, rather than reporting original trial data.

SEP 5, 2026 · JOURNAL ARTICLE

Real-World Testing Landscape and Costs of Companion Diagnostics and Comprehensive Genomic Profiling Across Nine Solid Tumors in Japan: A 10-Year Analysis

Oncology and Therapy

Retrospective real-world database analysis of testing utilization and costs across nine cancer types; descriptive findings on patterns and cost variation, but without comparative efficacy, clinical outcome, or causal inference.

SEP 4, 2026 · JOURNAL ARTICLE

ctDNA-based detection of residual disease: implications for management of non-metastatic NSCLC

Frontiers in Oncology

A narrative review synthesizing biological foundations, technological approaches, and current evidence for ctDNA-based MRD detection in non-metastatic NSCLC, without reporting original trial data or effect sizes.

AUG 18, 2026 · JOURNAL ARTICLE

Clinical Application of Circulating Tumor DNA in Surgically Treated Esophageal Squamous Cell Carcinoma

Annals of Laboratory Medicine

A prospective single-centre study in 84 ESCC patients shows ctDNA detection correlates with stage and precedes radiological recurrence in some cases, but lacks a formal comparator group and hard clinical outcome validation.

AUG 18, 2026 · JOURNAL ARTICLE

Modeling KRAS mutations in KMT2A::MLLT3 acute myeloid leukemia promotes leukemic progression and transcriptional rewiring

Leukemia

A mechanistic preclinical model study with supporting clinical cohort data showing KRAS mutations accelerate KMT2A::MLLT3 AML progression; limited by in vivo mouse model design and observational patient data without controlled comparison.